Last ¥1,887 JPY
Change Today -5.00 / -0.26%
Volume 1.2M
4568 On Other Exchanges
As of 2:00 AM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

daiichi sankyo co ltd (4568) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/10/14 - ¥2,007
52 Week Low
08/8/13 - ¥1,581
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DAIICHI SANKYO CO LTD (4568)

Related News

No related news articles were found.

daiichi sankyo co ltd (4568) Related Businessweek News

No Related Businessweek News Found

daiichi sankyo co ltd (4568) Details

Daiichi Sankyo Company, Limited is engaged in the research, development, manufacture, import, sale, and marketing of pharmaceutical products in Japan and internationally. Its principal products include Olmesartan, an anti-hypertensive agent; Prasugrel, an antiplatelet agent; Memary and Donepezil for the treatment of alzheimer’s disease; Nexium for treating reflux esophagitis, etc.; Inavir, an anti-influenza treatment product; ActHIB, a haemophilus b conjugate vaccine; and Loxonin S, an analgesic and anti-inflammatory drug. The company’s products also include Denosumab, an antibody for the treatment and prevention of various bone disorders; and Edoxaban, an oral anticoagulant product. In addition, it markets therapies in hypertension, dyslipidemia, diabetes, acute coronary syndrome, and metastatic melanoma. Further, the company develops, manufactures, and sells non-prescription medications, non-medical goods, cosmetics, and food products; medical devices for healthcare professionals, clinics, and hospitals; drinking water; and pharmaceuticals and drugs for animals, as well as researches, develops, manufactures, and sells vaccines. Additionally, it is involved in the manufacture and contract manufacture of as active pharmaceutical ingredients and intermediates, as well as in the provision of insurance and real estate agency services. The company has a strategic collaboration with Coherus BioSciences, Inc. for the development and commercialization of biosimilar candidates; strategic alliance with Sanford-Burnham Medical Research Institute to study novel drug targets in cardiovascular-metabolic diseases; and clinical collaboration agreement with Portola Pharmaceuticals, Inc. for Phase III studies of Factor Xa Inhibitor Antidote, Andexanet Alfa, and Edoxaban. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.

32,791 Employees
Last Reported Date: 06/23/14
Founded in 1899

daiichi sankyo co ltd (4568) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

daiichi sankyo co ltd (4568) Key Developments

Portola Pharmaceuticals Enters into Clinical Collaboration Agreement with Daiichi Sankyo for Phase 3 Studies of Factor Xa Inhibitor Antidote, Andexanet Alfa, and Edoxaban

Portola Pharmaceuticals announced that it has entered into a second clinical collaboration agreement with Daiichi Sankyo to study andexanet alfa, Portola's investigational Factor Xa inhibitor antidote, in Phase 3 registration studies with Daiichi Sankyo's Factor Xa inhibitor edoxaban. Portola's original collaboration agreement with Daiichi Sankyo, announced in June 2013, covered the conduct of a Phase 2 proof-of-concept study, for which results are anticipated later this year. The Phase 3 edoxaban studies, known as ANNEXA(TM) - E (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors - Edoxaban), are expected to start in 2015. Under this non-exclusive collaboration agreement, Portola will receive an upfront payment and is eligible to receive additional development and regulatory milestone payments. Portola retains full, worldwide commercial rights to andexanet alfa, for which Portola is pursuing an Accelerated Approval pathway.

Pieris AG Achieves Milestone Payment in Daiichi Sankyo Company, Limited Collaboration to Develop Anticalin Therapeutics

Pieris AG announced that it has achieved its second program, and fifth milestone overall, in its discovery and development collaboration with Daiichi Sankyo Company Limited, triggering an undisclosed payment. The milestone is based on successful in vitro and in vivo studies validating a range of Anticalin(R) targeted protein drug candidates designed to bind a Daiichi Sankyo target. With this achievement, Pieris will transfer development responsibility of the program to Daiichi Sankyo, who will initiate further in vivo studies in non-human primates. Under the terms of the 2011 agreement, Pieris receives committed research funding and payments for the achievement of research, preclinical, regulatory and commercial milestones. The partnership could encompass for Pieris more than EUR 100 million per program in license fees, funding and milestones, not including royalties on sales from marketed Anticalin proteins resulting from the collaboration. Daiichi Sankyo will have exclusive marketing rights worldwide for all such products.

South Korean Court Invalidates Composition Patent for Daiichi Sankyo (Japan)'s Olmetec Plus

South Korea's Intellectual Property Tribunal has ruled that the composition patent covering Daiichi Sankyo (Japan)'s antihypertensive Olmetec Plus (olmesartan + hydrochlorothiazide) is invalid. The court made its ruling following on from a challenge by 17 generic manufacturers of the drug, which included local firms Dong-A, Choongwae, Kukjei, JRP, Kolon, Ahngook, Pharmaking, Ilyang, Ildong, and Chong Kun Dang. Olmetec Plus' composition patent had been due to expire in 2021, but the expiry of Olmetec (olmesartan)'s patent last autumn had prompted a number of companies to not only launch generic versions of olmesartan, but also combinations of olmesartan and other drugs. Indeed, more than half of the new launches were reportedly olmesartan combinations. It is not yet known whether Daiichi Sankyo will appeal against the Intellectual Property Tribunal's ruling.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4568:JP ¥1,887.00 JPY -5.00

4568 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioCryst Pharmaceuticals Inc $12.86 USD +0.61
BioMerieux €77.75 EUR +0.25
Exelixis Inc $4.27 USD -0.06
Ipsen SA €33.25 EUR +0.35
Vertex Pharmaceuticals Inc $92.01 USD -3.55
View Industry Companies

Industry Analysis


Industry Average

Valuation 4568 Industry Range
Price/Earnings 22.2x
Price/Sales 1.2x
Price/Book 1.4x
Price/Cash Flow 22.3x
TEV/Sales 0.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAIICHI SANKYO CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at